In vitro activity of novel rifamycins against gram-positive clinical isolates

被引：9

作者：

Murphy, Christopher K.

Karginova, Elena

Sahm, Dan

Rothstein, David M.

机构：

[1] ActivBiot Inc, Lexington, MA 02421 USA

[2] Eurofins Medinet Inc, Anti Infect Serv, Herndon, VA 20171 USA

来源：

JOURNAL OF ANTIBIOTICS | 2007年 / 60卷 / 09期

关键词：

rifampin; rifalazil; ABI-0043; staphylococci; streptococci; MIC;

D O I：

10.1038/ja.2007.72

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC(90)s of 0.008 and 0.0005 mu g/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.

引用

收藏

页码：572 / 576

页数：5

相关论文

共 21 条

[1] Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus [J].

Aubry-Damon, H ;

Soussy, CJ ;

Courvalin, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2590-2594

[2] Structural mechanism for rifampicin inhibition of bacterial RNA polymerase [J].

Campbell, EA ;

Korzheva, N ;

Mustaev, A ;

Murakami, K ;

Nair, S ;

Goldfarb, A ;

Darst, SA .

CELL, 2001, 104 (06) :901-912

[3]

Clinical and Laboratory Standards Institute, 2006, M100S16 CLIN LAB STA

[4] IN-VITRO AND IN-VIVO ANTIBACTERIAL ACTIVITIES OF KRM-1648 AND KRM-1657, NEW RIFAMYCIN DERIVATIVES [J].

FUJII, K ;

TSUJI, A ;

MIYAZAKI, S ;

YAMAGUCHI, K ;

GOTO, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :1118-1122

[5] RIFAMPICIN IN FREE COMBINATION WITH OTHER ANTI-MICROBIAL DRUGS IN NON-TB INFECTIONS - CLINICAL-DATA ON 650 PATIENTS - (A REVIEW) [J].

KISSLING, M ;

BERGAMINI, N .

CHEMOTHERAPY, 1981, 27 (05) :368-402

[6] Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis [J].

Kutlin, A ;

Kohlhoff, S ;

Roblin, P ;

Hammerschlag, MR ;

Riska, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :903-907

[7] TREATMENT OF EXPERIMENTAL STAPHYLOCOCCAL INFECTIONS - EFFECT OF RIFAMPIN ALONE AND IN COMBINATION ON DEVELOPMENT OF RIFAMPIN RESISTANCE [J].

MANDELL, GL ;

MOORMAN, DR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (04) :658-662

[8] Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes [J].

Mullin, S ;

Rothstein, DM ;

Murphy, CK .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) :1908-1909

[9] In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus [J].

Murphy, CK ;

Mullin, S ;

Osburne, MS ;

van Duzer, J ;

Siedlecki, J ;

Yu, X ;

Kerstein, K ;

Cynamon, M ;

Rothstein, DM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :827-834

[10] Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection [J].

Rothstein, David M. ;

Farquhar, Ronald S. ;

Sirokman, Klari ;

Sondergaard, Karen L. ;

Hazlett, Charles ;

Doye, Angelia A. ;

Gwathmey, Judith K. ;

Mullin, Steve ;

van Duzer, John ;

Murphy, Christopher K. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) :3658-3664